The superior anti-colitic effects of VCAM-1 antibody blockade compared to other endothelial CAM targets were later corroborated by Soriano et al [55], who demonstrated that chronic treatment with MK1.91 anti-VCAM-1 mAbs, but not with ICAM-1 mAb or MAdCAM-1 mAbs, significantly improved dextran sodium sulphate (DSS)-induced murine colitis. This evidence concerns the gene VCAM1 and colitis.